Biotech · Public company · Bala Cynwyd, PA, US

Larimar Therapeutics, Inc.

Ticker LRMR · SEC CIK 0001374690

Track this companyFree. Adds Larimar Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials82 recruiting or active

Pipeline programs4From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline4

NomlabofuspPhase 3 · Friedreich AtaxiaClinicalTrials.gov · fetched Nov 12, 2026
CTI-1601Phase 2 · Friedreich AtaxiaClinicalTrials.gov · fetched Nov 12, 2026
Buccal Swabs and Blood DrawsFriedreich AtaxiaClinicalTrials.gov · fetched Nov 12, 2026
Buccal Swabs, Blood Draws and Skin Punch BiopsyFriedreich AtaxiaClinicalTrials.gov · fetched Nov 12, 2026

A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's AtaxiaPHASE3 · RECRUITING · started Oct 26, 2026ClinicalTrials.gov NCT07778836 · fetched Nov 12, 2026
A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's AtaxiaPHASE1 · TERMINATED · started Dec 6, 2024ClinicalTrials.gov NCT06681766 · fetched Nov 12, 2026
An Open-Label Study of CTI-1601 in Subjects With Friedreich's AtaxiaPHASE2 · RECRUITING · started Jan 25, 2024ClinicalTrials.gov NCT06447025 · fetched Nov 12, 2026
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's AtaxiaPHASE2 · COMPLETED · started Sep 21, 2022ClinicalTrials.gov NCT05579691 · fetched Nov 12, 2026
Determine Range of Tissue Frataxin Concentrations and Other Potential BiomarkersCOMPLETED · started Aug 4, 2021ClinicalTrials.gov NCT05028764 · fetched Nov 12, 2026
Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaPHASE1 · COMPLETED · started Jul 31, 2020ClinicalTrials.gov NCT04519567 · fetched Nov 12, 2026
A Study to Assess Variation in Potential Biomarkers in Friedreich AtaxiaCOMPLETED · started Jan 14, 2020ClinicalTrials.gov NCT04255680 · fetched Nov 12, 2026
Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaPHASE1 · COMPLETED · started Dec 11, 2019ClinicalTrials.gov NCT04176991 · fetched Nov 12, 2026